Capital Advisory Group Advisory Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150	Closed	-$14K	–	422
2021 Q3	$14K	Hold	150	–	–	0.01%	368
2021 Q2	$14K	Hold	150	–	–	0.01%	367
2021 Q1	$17K	Hold	150	–	–	0.01%	328
2020 Q4	$21K	Sell	150 -150	-50%	-$17.8K	0.01%	310
2020 Q3	$25K	Hold	300	–	–	0.01%	243
2020 Q2	$23K	Hold	300	–	–	0.01%	244
2020 Q1	$13K	Buy	+300	New	+$15.6K	0.02%	206
2019 Q4	–	Sell	-300	Closed	-$13K	–	364
2019 Q3	$13K	Hold	300	–	–	0.01%	254
2019 Q2	$19K	Hold	300	–	–	0.01%	226
2019 Q1	$21K	Buy	+300	New	+$17.1K	0.02%	206

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Advisory Group Advisory Services's RARE Position: Q4 2021 in Review

Capital Advisory Group Advisory Services sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 150 shares — an estimated $14K sold.

Capital Advisory Group Advisory Services first reported a position in RARE in Q1 2019 and held it in 10 quarters. The position peaked at $25K in Q3 2020. 235 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

Capital Advisory Group Advisory Services reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 150 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $14K.
Capital Advisory Group Advisory Services first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and held it in 10 quarters.
Capital Advisory Group Advisory Services's Ultragenyx Pharmaceutical position peaked at $25K in Q3 2020.
235 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on Capital Advisory Group Advisory Services's 13F filing for Q4 2021, filed 15 Feb 2022.